Benzinga · Oct 27, 2026
BTIG Reiterates Buy on Jade Biosciences, Maintains $77 Price Target
BTIG analyst Julian Harrison reiterates Jade Biosciences (NASDAQ:JBIO) with a Buy and maintains $77 price target.
JB
NASDAQ · JBIO
Jade Biosciences, Inc.
Healthcare · Biotechnology
$14.06
Down-$0.13 (-0.92%)
Updated Nov 3, 2026, 12:57 AM
SID Score
4.6/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 484.17M
- P/E ratio
- -9
- Dividend yield
- 0.00%
- 52-week range
- $12.45 – $28.00
- Volume
- 682.31K
- Avg. volume
- 195K
Price performance · JBIO
JBIO price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
JBIO closed at $14.06 after 20 trading sessions, down 0.07% for the selected period.
- Last close
- $14.06
- Period change
- -0.07%
- Period low
- $13.41
- Period high
- $15.13
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $14.13 | $14.35 | $13.83 | $14.06 | 682.31K |
| Oct 29, 2026 | $14.715 | $14.93 | $14.16 | $14.24 | 896.09K |
| Oct 28, 2026 | $14.59 | $14.90 | $14.13 | $14.59 | 671.52K |
| Oct 27, 2026 | $14.52 | $15.065 | $14.355 | $14.74 | 652.9K |
| Oct 26, 2026 | $14.69 | $15.04 | $14.36 | $14.50 | 477.46K |
| Oct 23, 2026 | $14.89 | $14.995 | $14.54 | $14.59 | 634.38K |
| Oct 22, 2026 | $15.04 | $15.44 | $14.3601 | $14.91 | 575.93K |
| Oct 21, 2026 | $14.84 | $15.43 | $14.72 | $15.13 | 932.73K |
| Oct 20, 2026 | $13.93 | $14.96 | $13.73 | $14.86 | 881.3K |
| Oct 19, 2026 | $13.86 | $14.10 | $13.54 | $13.83 | 828.51K |
| Oct 16, 2026 | $13.78 | $14.10 | $13.03 | $13.47 | 981.01K |
| Oct 15, 2026 | $13.54 | $14.18 | $13.45 | $13.76 | 1.04M |
| Oct 14, 2026 | $13.22 | $13.655 | $12.8465 | $13.44 | 1.17M |
| Oct 13, 2026 | $14.00 | $14.235 | $13.35 | $13.42 | 1.33M |
| Oct 12, 2026 | $14.33 | $14.445 | $13.82 | $14.00 | 1.36M |
| Oct 9, 2026 | $14.16 | $14.81 | $14.00 | $14.39 | 735.6K |
| Oct 8, 2026 | $13.58 | $14.15 | $13.18 | $14.15 | 1.67M |
| Oct 7, 2026 | $13.19 | $14.14 | $13.08 | $13.77 | 951.27K |
| Oct 6, 2026 | $14.20 | $14.335 | $13.15 | $13.41 | 493.87K |
| Oct 5, 2026 | $14.21 | $14.705 | $13.79 | $14.07 | 607.06K |
Latest JBIO news
The latest Smart Investors Daily articles mentioning JBIO.
Stock researchCompany · Overview
Company
Market Activity
Research & News
JBIO research
Overview
Company profile and research snapshot.
Company profile
Jade Biosciences Inc is focused on developing therapies to address critical unmet needs in autoimmune diseases. Its asset, JADE-001, will target the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial. Jade's pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $21.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 27, 2026 | BTIG | Buy | — |
| Oct 1, 2026 | Wedbush | Outperform | — |
| Oct 1, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 11, 2026 | Wedbush | Outperform | — |
| Aug 10, 2026 | BTIG | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 21, 2026
Jade Biosciences to Highlight Advancement of JADE101 Development Program at American Society of Nephrology (ASN) Kidney Week 2026
EVERGREEN Phase 3 Trial-in-Progress poster presents planned study design of JADE101 in IgA nephropathy; initiation now expected in the fourth quarter of 2026JUNIPER Phase 2 Trial-in-Progress poster highlights ongoing study of JADE101 in IgA nephropathy; interim data now expected in the second quarter of 2027 SAN FRANCISCO and VANCOUVER, British Columbia, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focus
Benzinga · Oct 1, 2026
Wedbush Reiterates Outperform on Jade Biosciences, Maintains $47 Price Target
Wedbush analyst Laura Chico reiterates Jade Biosciences (NASDAQ:JBIO) with a Outperform and maintains $47 price target.
Benzinga · Oct 1, 2026
HC Wainwright & Co. Reiterates Buy on Jade Biosciences, Maintains $55 Price Target
HC Wainwright & Co. analyst Arthur He reiterates Jade Biosciences (NASDAQ:JBIO) with a Buy and maintains $55 price target.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
